Unnamed Lilly "Mirror Fund" Acquires First Two Compounds
This article was originally published in The Pink Sheet Daily
The acquisitions of two drug candidates - one from Lilly, one from a university - are the first in the pharma's latest scheme to share risk with VCs.
You may also be interested in...
Atlas pledges to explore areas of mutual interest to the firm and its new corporate limited partners, but the drug firms won’t receive exclusive rights to anything in the new fund’s portfolio.
The pharma pledges $50 million to the California firm’s new seventh round, which it anticipates closing more than eight years after its sixth. For GSK, it’s the latest tie-up with a VC firm as part of a regional investment strategy.
Lilly and Canadian VCs back a new TVM Life Sciences fund that will invest in a network of single-asset companies in Quebec.